Mason & Associates (California)’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$852K Buy
2,352
+101
+4% +$34.6K 0.14% 83
2026
Q1
$786K Hold
2,251
0.15% 77
2025
Q4
$737K Buy
2,251
+266
+13% +$84.4K 0.14% 81
2025
Q3
$560K Sell
1,985
-87
-4% -$25.2K 0.11% 78
2025
Q2
$579K Hold
2,072
0.13% 72
2025
Q1
$646K Buy
2,072
+42
+2% +$12.4K 0.16% 64
2024
Q4
$529K Sell
2,030
-243
-11% -$72.1K 0.12% 70
2024
Q3
$733K Buy
2,273
+210
+10% +$68.7K 0.18% 58
2024
Q2
$645K Buy
2,063
+308
+18% +$90.5K 0.17% 56
2024
Q1
$499K Sell
1,755
-280
-14% -$81.9K 0.13% 63
2023
Q4
$586K Sell
2,035
-313
-13% -$85.3K 0.17% 47
2023
Q3
$631K Buy
2,348
+8
+0.3% +$2K 0.2% 44
2023
Q2
$520K Buy
2,340
+9
+0.4% +$2.09K 0.15% 52
2023
Q1
$563K Buy
2,331
+309
+15% +$75.9K 0.17% 44
2022
Q4
$531K Sell
2,022
-26
-1% -$6.97K 0.17% 45
2022
Q3
$462K Buy
2,048
+40
+2% +$9.7K 0.16% 47
2022
Q2
$489K Buy
2,008
+7
+0.3% +$1.72K 0.17% 51
2022
Q1
$484K Buy
2,001
+856
+75% +$197K 0.15% 69
2021
Q4
$257K Buy
+1,145
New +$242K 0.08% 84

Other funds holding AMGN

Mason & Associates (California)'s AMGN Position: Q2 2026 in Review

Mason & Associates (California) increased its Amgen (AMGN) stake by 4.5% in Q2 2026, buying an estimated $34.6K and bringing the position to 2,352 shares worth $852K. The position accounts for 0.14% of the portfolio, ranked #83.

Mason & Associates (California) first reported a position in AMGN in Q4 2021 and has held it in 19 quarters since. 3,139 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Mason & Associates (California) held 2,352 shares of Amgen worth $852K as of Q2 2026.
  • Mason & Associates (California) bought 101 Amgen shares in Q2 2026, an estimated $34.6K.
  • Amgen made up 0.14% of Mason & Associates (California)'s portfolio in Q2 2026, its #83 holding.
  • Mason & Associates (California) first reported a position in Amgen in Q4 2021 and has held it in 19 quarters since.
  • 3,139 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Mason & Associates (California)'s 13F filing for Q2 2026, filed 23 Jul 2026.